Published in pharmaceutical
As Hospital 57357 is keen to protect its children patients and offer them safe medications, its proteomic and metabolomics research team explores new eras seeking better patient outcome. It is known that chemotherapy carries toxic side effects on different body organs. Methotrexate (MTX) is a widely used medication to treat numerous malignancies; however, its use is associated with marked liver damage (hepatotoxicity).
In cooperation with Tanta university, 57357’s proteomics and metabolomics research unit made a set of trials on animals using different plant extracts to find that the methanol extract from a certain plant species (Salvinia auriculata methanol extract or SAME) prevents the liver damage induced by MTX. Experiments showed that pretreatment with the methanol extract provided a promising protective effect against hepatotoxicity (or liver damage) caused by methotrexate. This protective effect could be due to the reduction in oxidative stress levels. Additionally, the extract has a remarkable anti-inflammatory and anti-apoptotic (= anti-cell death) activity. Hence, methanol extract from Salvinia auriculata (the plant) has the potential to be a powerful chemical substance to prevent liver damage. In addition, the extract exhibited antibacterial activity against a pathogenic bacteria called Acinetobacter baumannii. Thus, findings revealed new evidence of the hepatoprotective (= protection effect against liver damage) and anti-bacterial properties of the methanol extract that need further future investigation. However, more investigations are required to ensure the therapeutic efficacy and safety of the extract to be used as an anti-bacterial and hepatoprotective chemical. The research performed by the proteomics and metabolomics team lead by Dr. Sameh Magdeldin was published in MDPI Pharmaceuticals journal with impact factor 5.86.
To read more: https://www.mdpi.com/1424-8247/15/5/549